Publications

H Jalal, T Trikalinos, F Alarid-Escudero (2021). BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling. Frontiers in Physiology.

F Alarid-Escudero, E Krijkamp, E Enns, A Yang, M Hunink, P Pechlivanoglou, H Jalal (2021). A Tutorial on Time-Dependent Cohort State-Transition Models in R using a Cost-Effectiveness Analysis Example.

G Baio (2020). survHE: Survival analysis for health economic evaluation and cost-effectiveness modelling. Journal of Statistical Software.

DOI JSS page Project Code

R Smith, P Schneider (2020). Making health economic models Shiny: A tutorial. Wellcome Open Research.

R Hart, D Burns, B Ramaekers, S Ren, D Gladwell, W Sullivan, N Davison, O Saunders, I Sly, T Cain, D Lee (2020). R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study. PharmacoEconomics.

E Krijkamp, F Alarid-Escudero, E Enns, P Pechlivanoglou, M Hunink, A Yang, H Jalal (2020). A Multidimensional Array Representationof State-Transition Model Dynamics. Medical Decision Making.

DOI PDF DARTH website Code

F Alarid-Escudero, K Kuntz (2020). Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio. PharmacoEconomics.

F Alarid-Escudero, E Krijkamp, E Enns, M Hunink, P Pechlivanoglou, H Jalal (2020). Cohort state-transition models in R: From conceptualization to implementation.

Preprint DARTH website

F Alarid-Escudero, E Krijkamp, E Enns, M Hunink, P Pechlivanoglou, H Jalal (2020). Cohort state-transition models in R: From conceptualization to implementation. arXiv.

E Jutkowitz, F Alarid-Escudero, K Kuntz, H Jalal (2019). The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. PharmacoEconomics.

A Hatswell, F Chandler (2019). Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling. Value in Health.

D Incerti, H Thom, G Baio, J Jansen (2019). R you still using Excel? Why we need modern software tools for health technology assessment. Value in Health.

F Alarid-Escudero, E Enns, K Kuntz, T Michaud, H Jalal (2019). “Time Traveling Is Just Too Dangerous” but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Value in Health.

F Alarid-Escudero, E Krijkamp, P Pechlivanoglou, H Jalal, SYZ Kao, A Yang, E Enns (2019). A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling. PharmacoEconomics.

F Alarid-Escudero, R MacLehose, Y Peralta, K Kuntz, E Enns (2018). Nonidentifiability in Model Calibration and Implications for Medical Decision Making. Medical Decision Making.

C Easterly, F Alarid-Escudero, E Enns, S Kulasingam (2018). Revisiting assumptions about age-based mixing representations in mathematical models of sexually transmitted infections. Vaccine.

E Krijkamp, F Alarid-Escudero, E Enns, H Jalal, M Hunink, P Pechlivanoglou (2018). Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. Medical Decision Making.

H Jalal, F Alarid-Escudero (2018). A Gaussian Approximation Approach for Value of Information Analysis. Medical Decision Making.

H Jalal, P Pechlivanoglou, E Krijkamp, F Alarid-Escudero, E Enns, M Hunink (2017). An Overview of R in Health Decision Sciences. Medical Decision Making.

C Williams, J Lewsey, A Briggs (2016). Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial . Medical Decision Making.

Project DOI PDF R-HTA link Code

G Baio, A Heath (2016). When simple becomes complicated: Why Excel should lose its place at the top table. Global & Regional Health Technology Assessment.